Sample of RNF Issue - Renal Dietitians (RPG)

Transcription

Renal Nutrition Forum
A Peer Reviewed Publication of the Renal Dietitians Dietetic Practice Group
Volume 31 • Number 4
In This Issue
1
Feature Article
2
Letter from the Editor
7
Nutrition-focused
Physical Examination:
Skin, Nails, Hair, Eyes,
and Oral Cavity
16
Member Spotlight
17
Member Spotlight
19
Member Spotlight
22
Calendar of Events
23
RPG Outstanding
Service Award Winner
24
RPG Chair Message
26
CRN Chairperson
Message
27
RPG Executive
Committee
www.renalnutrition.org
Binder Bracelet Activity
to Help Improve Binder
Medication Compliance
and Serum Phosphorus in
Hemodialysis Patients
Abstract:
Molly Ennis, RD, LD
Graduate Student
Department of Nutrition and Dietetics
Saint Louis University
Saint Louis, MO
Email: [email protected]
Mildred Mattfeldt-Beman, PhD, RD, LD
Department Chair and Professor
Saint Louis, MO
Amy R. Moore, MPH, MS, RD, LD
DPD Director, Instructor
Saint Louis, MO
Ajlina Karamehic-Muratovic, PhD
Assistant Professor
Department of Sociology and Criminal Justice
Saint Louis, MO
This article has been approved for 1.5
CPE units. The online CPEU quiz and
certificate of completion can be accessed in
the Members Only section of the RPG web
site via the My CPEU link. This CPE offering
is available to current RPG members only
and the expiration date is October 15, 2013.
Renal Nutrition Forum • Vol. 31 • No. 4
1
RPG
Renal Nutrition Forum is
published quarterly (summer,
fall, winter, spring) as a peerreviewed publication of the
Renal Dietitians Dietetic
Practice Group of the Academy
of Nutrition and Dietetics.
From the Editor’s Desk
Sara Erickson, RD, CSR, LDN, CNSC
Editor
The views expressed in this
publication are those of the
author and are not necessarily
those of The Academy of Nutrition
and Dietetics. Publication of an
advertisement in the Forum
should not be construed as
endorsement by the RPG of the
product or the advertiser.
Articles about successful
programs, research
interventions, evaluations
and treatment strategies,
educational materials,
meeting announcements and
information about educational
programs are welcome and
should be emailed to the editor
by the next deadline.
Future Deadlines:
December 1, 2012
March 1, 2013
June 1, 2013
September 1, 2013
Please forward information to:
[email protected]
Subscription cost is $35.00 for
individuals who are ineligible
for Academy membership and
$50.00 for institutions.
A check or money order should
be made payable to AND/DPG
#21 and sent to:
Stacey C. Phillips, MS, RD
4360 4 Mile Road NE
Grand Rapids, MI 49525
Remember to update your
profile electronically in the
‘members only’ section of
the Academy’s web site. You
will need your registration
number and web password.
Keeping the Academy
informed of your name and
contact information will help
avoid delayed issues of your
Renal Nutrition Forum.
2
Calling All Authors!
Renal Nutrition Forum Article
Submissions Needed!
If you have ever considered submitting an
article to the RNF now is the time!
Please consider sharing your work with
fellow RPG members or reaching
out to colleagues to inquire about work
they may be interested in submitting.
We guarantee publication!
For more information, please contact
RNF Editor, Sara Erickson at
[email protected]
Feature Article...
Introduction:
Methods:
3
Feature Article...
4
Feature Article...
5
Feature Article...
References
Eileen Katz, MS, RD, LD
Kelly Ziemkiewicz, RD, LD, CDE
Lynn Munson, MS, RD, LD
Amy Hess-Fishl, MS, RD, LDN, BC-ADM, CDE
6
Advances in Practice
Nutrition-focused Physical Examination:
Skin, Nails, Hair, Eyes, and Oral Cavity
Cassandra Pogatshnik, RD, LD, CNSC
Nutrition Support Dietitian
Cleveland Clinic
Cleveland, OH
Cindy Hamilton, MS, RD, LD, CNSD
Director, Center for Human Nutrition
Cleveland Clinic
Cleveland, OH
This article has been approved for 1.5 CPE units. The online
CPEU quiz and certificate of completion can be accessed in the
Members Only section of the RPG web site via the My CPEU
link. This CPE offering is available to current RPG members
only and the expiration date is October 15, 2013.
©2012 Support Line, Dietitians in Nutrition Support, a dietetic
practice group of the Academy of Nutrition and Dietetics. Used
with permission.
Abstract
Introduction
7
Advances in Practice...
Getting Started
Skin
Figure 1.
8
Advances in Practice..
Table 2.
9
Table 2.
10
Case #1 Dehydration
Nutrition Support Access Devices
11
Figure 2.
Figure 3.
Hair
Nails
12
Case #2 Overhydration
Orofacial Examination
13
Conclusion
References
Do you know of a product,
service, or message that would
benefit your fellow renal
dietitians and renal patients?
Share the information with
over 2,500 renal dietitians!
Contact RPG Ad Editor at
[email protected]
14
RPG WEBSITE & ELECTRONIC MEDIA HIGHLIGHTS
Some exciting new additions & updates!
ONLINE STORE:
ONLINE WEBSITE POLLMembership Feedback:
2 NEW AWESOME MEMBER BENEFITS NOW AVAILABLE:
TRY THESE LINKS……..
Go confidently in the direction of your
dreams. Live the life you have imagined.
– HENRY DAVID THOREAU
Visit RPG’s web site: www.renalnutrition.org for CPEU offerings and
valuable professional and patient resources
15
Member Spotlight
A report from the NKF Spring Clinical
Meeting 2012: Implications of Dietary
Additives in Kidney Disease
Peggy Harum, RD, LD
Renal Dietitian
Texas Renal Ventures
Ft. Worth, TX
Recipient of an RPG educational stipend for the 2012 National
Kidney Foundation Spring Clinical Meeting in Washington D.C.
References
CSR Exams have been updated!
For more information please visit the
following sites:
Examination Format:
http://www.cdrnet.org/certifications/spec/
newexaminationformatrenal.cfm
Content Outline and Reference List:
http://www.cdrnet.org/certifications/spec/renal.cfm
Updated Examination Dates and Fee Schedule:
http://www.cdrnet.org/certifications/spec/renaldates.cfm
New Online Eligibility Application:
http://www.cdrnet.org/certifications/spec/
newonlineeligibilityapplication.cfm
16
Member Spotlight
NKF Inflammation Workshop Review
Terri Tomak, RD, CSR
Renal Dietitian
Sparrow Health System Outpatient Dialysis Center
Lansing, MI
Recipient of an RPG educational stipend for the 2012 National Kidney
Foundation Spring Clinical Meeting held in Washington D.C.
17
Member Spotlight
Nutrition
designed for
people on dialysis
s Excellent source of high-quality protein
to help meet nutritional needs and
replace protein lost during dialysis
Use under medical supervision.
*
Available Through
s Low in phosphorus,
potassium and sodium
Homemade Vanilla bottles only available at retail locations.
Also in pharmacy section next to Glucerna® at:
s www.abbottstore.com
s Home Delivery (1-800-986-8502)
©2012 Abbott Laboratories
84900/July 2012 LITHO IN USA
18
Member Spotlight
NKF Kidney Stones 101 Workshop Review
Calcium
Renal Dietitian
Kidney Specialists of Minnesota
Brooklyn Center, MN
Sodium
Oxalate
Fluid
Lemonade
19
Member Spotlight
Protein/Meat
Dietary Oxalates and Kidney Stones Facts
References
20
Brief Summary: Consult full package insert for complete Prescribing Information.
INDICATIONS AND USAGE: Phoslyra® (calcium acetate oral solution 667 mg per 5 mL) is a phosphate
binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD).
Management of elevated serum phosphorus levels usually includes all of the following: reduction in dietary
intake of phosphate, removal of phosphate by dialysis, and inhibition of intestinal phosphate absorption with
phosphate binders.
DOSAGE AND ADMINISTRATION: The recommended initial dose of Phoslyra for the adult dialysis
patient is 10 mL with each meal. Increase the dose gradually to lower serum phosphorus levels to the
arget range, as long as hypercalcemia does not develop. Titrate the dose every 2 to 3 weeks until an
acceptable serum phosphorus level is reached. Most patients require 15–20 mL with each meal.
CONTRAINDICATIONS: Patients with hypercalcemia.
WARNINGS AND PRECAUTIONS:
Hypercalcemia. Patients with end stage renal disease may develop hypercalcemia when treated with
calcium, including calcium acetate (Phoslyra). Avoid the concurrent use of calcium supplements, including
calcium-based nonprescription antacids, with Phoslyra. An overdose of Phoslyra may lead to progressive
hypercalcemia, which may require emergency measures.Therefore, early in the treatment phase during the
dosage adjustment period, monitor serum calcium levels twice weekly. Should hypercalcemia develop,
reduce the Phoslyra dosage or discontinue the treatment, depending on the severity of hypercalcemia.
More severe hypercalcemia (Ca >12 mg/dL) is associated with confusion, delirium, stupor and coma.
Severe hypercalcemia can be treated by acute hemodialysis and discontinuing Phoslyra therapy.
Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia,
nausea, and vomiting. Mild hypercalcemia is usually controlled by reducing the Phoslyra dose or temporarily
discontinuing therapy. Decreasing or discontinuing Vitamin D therapy is recommended as well.
Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification. Radiographic
evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification.
The long-term effect of Phoslyra on the progression of vascular or soft tissue calcification has not been
determined.
Hypercalcemia (>11 mg/dL) was reported in 16% of patients in a 3-month study of a solid dose
formulation of calcium acetate; all cases resolved upon lowering the dose or discontinuing treatment.
Maintain the serum calcium-phosphorus product (Ca X P) below 55 mg2/dL2.
Concomitant Use with Medications. Hypercalcemia may aggravate digitalis toxicity. Phoslyra
contains maltitol (1 g per 5 mL) and may induce a laxative effect, especially if taken with other products
containing maltitol.
ADVERSE REACTIONS: No clinical trials have been performed with Phoslyra in the intended population.
Because the dose and active ingredients of Phoslyra are equivalent to that of the calcium acetate gelcaps
or tablets, the scope of the adverse reactions is anticipated to be similar.
Hypercalcemia is discussed elsewhere [see Warnings and Precautions].
Clinical Trial Experience. Because clinical trials are conducted under widely varying
conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to
rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
In clinical studies, calcium acetate has been generally well tolerated.
The solid dose formulation of calcium acetate was studied in a 3-month, open-label, nonrandomized study of 98 enrolled ESRD hemodialysis patients and in a two week double-blind, placebocontrolled, cross-over study with 69 enrolled ESRD hemodialysis patients. Adverse reactions (>2% on
treatment) from these trials are presented in Table 1.
Table 1: Adverse Reactions in Patients with End-Stage Renal Disease Undergoing Hemodialysis
In patients with ESRD...
Take as is
First and only FDA-approved
little LIQUID phosphate binder
• May lessen pill burden
• Potential to reduce optional fluid intake
associated with administration of solid PBs
• No water required
• Premixed—No need to reconstitute or dissolve in water
• No refrigeration, even after opening
Double-blind, placeboTotal adverse
3-mo, open-label
controlled, cross-over study
reactions reported
study of
of calcium acetate
for calcium acetate calcium acetate
n=69
n=167
n=98
Calcium acetate Placebo
n (%)
n (%)
n (%)
Preferred Term
n (%)
0 (0.0)
0 (0.0)
Nausea
6 (3.6)
6 (6.1)
Vomiting
4 (2.4)
4 (4.1)
0 (0.0)
0 (0.0)
Hypercalcemia
21 (12.6)
5 (7.2)
0 (0.0)
16 (16.3)
Calcium acetate oral solution was studied in a randomized, controlled, 3-arm, open label, cross-over, singledose study comparing calcium acetate oral solution to a solid formulation in healthy volunteers on
a controlled diet. Of the observed drug-related adverse reactions, diarrhea (5/38, 13.2%) was more common
with the oral solution.
Postmarketing Experience. The following additional adverse reactions have been identified during
post-approval of calcium acetate: dizziness, edema, and weakness.
DRUG INTERACTIONS: The drug interaction profile of Phoslyra is characterized by the potential of
calcium to bind to drugs with anionic functions (e.g., carboxyl, carbonyl, and hydroxyl groups). Phoslyra may
decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism.
There are no empirical data on avoiding drug interactions between calcium acetate or Phoslyra and most
concomitant drugs. When administering an oral medication with Phoslyra where a reduction in the
bioavailability of that medication would have a clinically significant effect on its safety or efficacy, administer
the drug one hour before or three hours after Phoslyra or calcium acetate. Monitor blood levels of the
concomitant drugs that have a narrow therapeutic range. Patients taking anti-arrhythmic medications for the
control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from
the clinical trials with all forms of calcium acetate.
Ciprofloxacin. In a study of 15 healthy subjects, a co-administered single dose of 4 calcium acetate
tablets (approximately 2.7 g) decreased the bioavailability of ciprofloxacin by approximately 50%.
USE IN SPECIFIC POPULATIONS
Pregnancy: Category C. Phoslyra contains calcium acetate. Animal reproduction studies have not been
conducted with Phoslyra, and there are no adequate and well controlled studies of Phoslyra use in
pregnant women. Patients with end stage renal disease may develop hypercalcemia with calcium acetate
treatment [see Warnings and Precautions]. Maintenance of normal serum calcium levels is important
for maternal and fetal well being. Hypercalcemia during pregnancy may increase the risk for maternal
and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and
hypoparathyroidism. Phoslyra treatment, as recommended, is not expected to harm a fetus if maternal
calcium levels are properly monitored during and following treatment.
Labor and Delivery. The effects of Phoslyra on labor and delivery are unknown.
Nursing Mothers. Phoslyra contains calcium acetate and is excreted in human milk. Human milk feeding
by a mother receiving Phoslyra is not expected to harm an infant, provided maternal serum calcium levels
are appropriately monitored.
Pediatric Use. Safety and effectiveness of Phoslyra in pediatric patients have not been established.
Geriatric Use. Clinical studies of calcium acetate did not include sufficient numbers of subjects aged
65 and over to determine whether they respond differently from younger subjects. Other reported clinical
experience has not identified differences in responses between the elderly and younger patients.
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of
the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of
concomitant disease or other drug therapy.
OVERDOSAGE: Administration of Phoslyra in excess of the appropriate daily dosage may result in
hypercalcemia [see Warnings and Precautions].
HOW SUPPLIED/STORAGE AND HANDLING: Phoslyra for oral administration is a clear solution
containing 667 mg calcium acetate per 5 mL. Phoslyra is supplied in a 473 mL (16 oz) amber-colored,
multiple-dose bottle, packaged with a marked dosing cup. Store at 25°C (77°F); excursions permitted to
15–30°C (59–86°F) [see USP Controlled Room Temperature]. The shelf life is 24 months.
PATIENT COUNSELING INFORMATION: Inform patients to take Phoslyra with meals, adhere to their
prescribed diets, and avoid the use of calcium supplements including nonprescription antacids. Inform
patients about the symptoms of hypercalcemia [see Warnings and Precautions and Adverse Reactions].
Advise patients who are taking an oral medication where a reduction in the bioavailability of that
medication would have a clinically significant effect on its safety or efficacy to take the drug one hour before
or three hours after Phoslyra.
Manufactured for:
Fresenius Medical Care North America
Waltham, MA 02451 1-800-323-5188
INDICATION:
Phoslyra® (calcium acetate oral solution, 667 mg per 5 mL) is a phosphate
binder (PB) indicated for the reduction of serum phosphorus in patients with
end stage renal disease (ESRD). Phoslyra is administered orally with food.
IMPORTANT SAFETY INFORMATION:
• Phoslyra is contraindicated in patients with hypercalcemia.
• Patients should have serum calcium levels closely monitored and
their dose of Phoslyra adjusted or terminated to bring levels to
normal. No other calcium supplements should be given concurrently with
Phoslyra.
• Phoslyra may decrease the bioavailability of tetracyclines or fluoroquinolones.
• There are no empirical data on avoiding drug interactions between calcium
acetate or Phoslyra and most concomitant drugs. When administering an
oral medication with Phoslyra where a reduction in the bioavailability of that
medication would have a clinically significant effect on its safety or
efficacy, administer the drug 1 hour before or 3 hours after Phoslyra or calcium
acetate. Monitor blood levels of the concomitant drugs that have a narrow
therapeutic range.
• The most common (>10%) adverse reactions experienced with Phoslyra are
hypercalcemia, nausea, and diarrhea.
• Phoslyra may cause diarrhea with nutritional supplements that contain maltitol.
For additional important safety information, please see brief Prescribing Information
on this page.
Manufactured by:
Lyne Laboratories
Brockton,MA 02301
For more information on Phoslyra, please contact Fresenius Medical Care NA at 800-323-5188. Manufactured for
and distributed by: Fresenius Medical Care NA, Waltham, MA 02451
Fresenius Medical Care and Phoslyra are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies.
All other trademarks are the property of their respective owners.
© 2012 Fresenius Medical Care NA.
101493-01 Rev. B 08/2012
101731-01 Rev. A 08/2012
Calendar of Events
October 2012
December 2012
April 2013
February 2013
May 2013
June 2013
March 2013
22
RPG Outstanding Service Award Winner!
Congratulations to the 2012
Outstanding Service Award Winner,
Jerrilynn D. Burrowes, PhD, RD, CDN!
23
RPG Chair Message
Sarah Kruger, MS, RD, CSR
RPG Chair
STAY TUNED FOR NEW &
UPDATED CSR WEBINARS!!!
The CSR Webinar Series is in the process of
being updated. The newly created webinar
modules will include detailed reviews on
disease state, lab values, interventions, and
case studies. These modules can be used to
study for the CSR exam as well as to ‘brush
up’ on clinical practice skills. RPG remains
committed to developing webinars with
topics of interest to enhance learning and
professional advancement!
New resources coming soon!
A collaborative project with DHCC is underway to
provide a webinar on Renal Patients in the Long
Term Care setting - stay tuned for more details! To
purchase other RPG produced Webinars please
visit www.renalnutrition.org/materials/index.php
24
Life-long Learning and Professional Development …
Dietetics Career Development Guide
Expert
Builds
lds and maintains know
knowledge,
skills and credentia
credentials
Advanced Practice
C ti
Continues
at the hi
ighest lev
vel of knowledge
highest
level
knowledge,
skills & behav
iorrs inclu
uding leadership,
behaviors
including
vision and /or advanced credential
Proficient
Operational Skills Obtained and Adeptly Practiced Long Term
May Begin to Acquire Specialist Credentials
Competent
Start of Practice after Registration
(Generally, the First Three Years of Practice)
Standards of
Practice (SOP)
Standards of
Professional
Performance
(SOPP)
Beginner
(Learning Phase)
Supervised Practice
DI
Dietetic Internship
CP
Coordinated Program
DTP
Dietetic Technician Program
Novice
}
CP
Coordinated Program
Didactic Education
DPD
DTP
Didactic Program in Dietetics Dietetic Technician Program
RD Pathways
Focus Area
DTR Pathway
Knowledge & Skills
EDUCATION FOR ENTRY INTO CAREER
Associate, Baccalaureate or Advanced Degree
Definition of Dietetics: Dietetics is the integration, application and communication of principles
derived from food, nutrition, social, business and basic sciences, to achieve and maintain optimal
nutrition status of individuals through the development, provision and management of effective
food and nutrition services in a variety of settings.
25
CRN Chairperson Message
Lisa Gutenkunst, MSEd, RD, CSR, CDN
NKF-CRN Chair
May 2012 Board Certified Specialist in Renal Nutrition (CSR) Recipients
Congratulations to the following Registered Dietitians!
California
Idaho
New Jersey
Ohio
Texas
Illinois
Florida
Nevada
Maryland
Georgia
Utah
Oklahoma
Virginia
New York
Oregon
Michigan
North Carolina
Washington
South Carolina
Hawaii
Missouri
26
Tennessee
Wisconsin
2012-2013 RPG Executive Committee
Mission:
Vision:
OFFICERS:
Chair
Sarah Kruger, MS, RD, CSR
[email protected]
Membership Services Outreach Chair
Nilima Desai, MPH, RD
[email protected]
Immediate Past Chair
Rachael Majorowicz, RD, LD
[email protected]
COMMITTEE CHAIRS:
Awards/Scholarship Chair
Sandy McDonald-Hangach, RD
[email protected]
Chair-Elect
Mary Kay Hensley, MS, RD, CSR
[email protected]
Mentor Chair
Open
Secretary
JoAnn Randazzo, RD, CDN
[email protected]
Professional Resource Center
Coordinator
Nadiya Lakhani, RD, LD
[email protected]
Treasurer
Stacey C. Phillips, MS, RD
[email protected]
Public Policy Chair
Sarah Motts, MS, RD, LDN
[email protected]
HOD Member
Pam Kent, MS, RD, CSR, LD
[email protected]
Social Media Chair
Sarah Coffin, MS, RD
[email protected]
RNF EDITORIAL BOARD:
RNF Editor
[email protected]
Webinar Chair
Annamarie Rodriguez, RD, LD
[email protected]
RNF Assistant Editor
Jackie Termont, RD
[email protected]
Projects Chair
Meg McCartney, RD, LDN
[email protected]
RNF Assistant Editor
Amy Braglia Tarpey, MS, RD, CSR, CNSC
[email protected]
iPad Subcommittee Chair
Melissa Prest , MS, RD, CSR, LDN
[email protected]
RNF Advertising Editor
Emily R. Cutler, MS, RD, LDN
[email protected]
Handouts Subcommittee Chair
Rita Milam, MA, RD, CSR, CDE, LD
[email protected]
Electronic Media Manager
Cathy M. Goeddeke-Merickel, MS, RD, LD
[email protected]
Website Reviewer
Subcommittee Chair
Erin Nelson, MPH, RD, LD
[email protected]
NOMINATING COMMITTEE:
Nominating Chair
Elizabeth Neumann, RD, LD
[email protected]
Nominating Member
Valerie Hannahs MS, RD, LD
[email protected]
Nominating Member
Betty Parry Fisher, MS, RD
[email protected]
Kidney Friendly Food Shelf Project
Chair
Lindsey Zirker RD, LD
[email protected]
ACADEMY CONTACT:
Manager, DPG Relations
Susan DuPraw, MPH, RD
800/877-1600 ext. 4814
[email protected]
For all inquiries please email: [email protected]
RNF Guidelines for Authors
Article length:
Article length is determined by the Editor for each
specific issue. The feature article (including abstract) is
approximately 3000 words (not including tables/graphs).
Other articles are usually 1000-1500 words; member
highlights and reports are approximately 400-500 words.
Text format:
Times New Roman font, 12 point, double space.
Tables/Illustrations:
Tables should be self-explanatory. All diagrams, charts
and figures should be camera-ready. Each should be
accompanied by a title and brief caption that clearly
explains the table, chart, diagram, figure, illustration, etc.
References:
References should be cited in the text in consecutive order
parenthetically. At the end of the text, each reference
should be listed in order of citation. The format should be
the same as the Journal of the Academy of Nutrition and
Dietetics.
Reference citation examples:
Article in periodical:
Knower WC, Barrett-Connor E, Fowler SE, et al. Reduction
in the incidence of type 2 diabetes with lifestyle
intervention or metformin. N Eng J Med. 2002;346:393–403.
Book:
Institute of Medicine. Dietary Reference Intakes: Applications
for Dietary Assessment. Washington, D.C.: National
Academy Press; 2001.
Chapter in a book:
Walsh J. Which insulin to use and how to start. In: Using
Insulin. San Diego, Calif.: Torry Pines Press; 2003.
Web site:
Medscape drug info. Available at www.medscape.com/
druginfo. Accessed August 15, 2011.
Author information:
List author with first name, middle initial (if any), last name,
professional suffix and affiliation below the title of the article.
Also include the primary author’s complete contact
information including affiliation, phone, fax and email address.
All submissions for publication should be submitted to the
editor as an email attachment (MS Word file). The feature
articles from the Renal Nutrition Forum will be posted on
the Members Only Section of the RPG website (password
protected). Thus, please include a brief abstract and 2-3
key words along with feature article submissions.
27
Editor, Renal Nutrition Forum
8954 Meadowmont View Drive
Charlotte, NC 28269
2012 Copyright by Renal Dietitians
Dietetic Practice Group of the Academy of
Nutrition and Dietetics. All rights reserved.
Visit the Renal Dietitians “Members Only Section”
for valuable patient and professional resources @
PRESORTED
STANDARD
US POSTAGE PAID
ROCHESTER MN
PERMIT NO. 289

Sample of RNF Issue - Renal Dietitians (RPG)

Transcription

Similar documents

View

Grand Junction (970) 263-7750 2464 US Hwy 6

Fall Into Place

JJ Virgin_Bio 04.14

MFHutton

collection 1295-98

The Maimed Kidney: When Is Endovascular Treatment Appropriate

Personal Hygiene

Abbott Nutrition

Business Alliance Forum Report. Accelerating GAIN.